Mar 17, 2026 | Aldeyra's Third FDA Rejection Crashes Stock 68%; CytomX Masked ADC Surges 60%

Aldeyra Therapeutics crashes ~68% after the FDA rejectsreproxalap for the third time. CytomX jumps 60%+ on masked ADC data in colorectal cancer. Pfizer's atirmociclib shows 40% PFS reduction in post-CDK4/6 breast cancer. Plus: court blocks RFK Jr. vaccine overhaul, MFN pricingreshapes deal structures, and Bicycle retreats from Padcev. Follow the podcast and visit our site at https://thepharmacloseout.com/#pharma,#pharmaceutical, #FDA, #clinical trials, #biotech, #drug approvals, #healthcare, #pharma podcast, #The Pharma #Closeout, #Aldeyra#Therapeutics, #reproxalap, #CRL, #dry eye disease, #CytomX, #varsetatug masetecan, #masked ADC, #colorectal cancer, #Pfizer, #atirmociclib, #Ibrance, #CDK4, #breast cancer, #Bicycle Therapeutics, #Padcev, #Rhythm Pharmaceuticals, #Imcivree, #RFK Jr,vaccine policy, #most favored nation, #MFN, #drug pricing, #GSK, #linerixibat, #Merck, #Sanofi, #Moderna